The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis

Thrombosis and Haemostasis

Volumn 86, Issue 6, 2001, Pages 1512-1520

  Cho, J H ^a   Yun, C H ^a   Seo, H S ^a   Koga, T ^a   Dan, T ^a   Koo, B A ^a   Kim, H Y ^a  

^a C and C Research Laboratories   (South Korea)

Author keywords

Antithrombotic effect; AT 1459; Bleeding time; Clotting times

Indexed keywords

4 [[1 [2 [2 [2 (6 AMIDINO 1 ETHYLINDOL 2 YL)ETHYL]PYROLIDINYL] 2 OXOETHYL] 2 OXOAZAPERHYDROEPIN 3 YL]AMINO]BUTANOIC ACID; ACTIVATED PROTEIN C; ARGATROBAN; AT 1459; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; DALTEPARIN; FERRIC CHLORIDE; KALLIKREIN; PLASMIN; THROMBIN; THROMBIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING TIME; BLOOD VESSEL FUNCTION; BOLUS INJECTION; CAROTID ARTERY THROMBOSIS; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME INHIBITION; EVALUATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBUS; VEIN THROMBOSIS;

EID: 0035655110     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616756     Document Type: Article

References (30)

1. Prevention of venous thromboembolism
2. Mechanisms of arterial thrombosis: Foundation for therapy
3. The human pharmacology of thrombin inhibition
4. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
5. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin
6. Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis, and its effects on the tail transection bleeding time
7. Antithrombotic activity or argatroban in experimental thrombosis in the rabbit
8. Argatroban as a potential anticoagulant in cardiopulmonary bypass - Studies in a dog model
9. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study
10. Activity of a subcutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis
11. Development of argatroban, a direct thrombin inhibitor, and its clinical application
12. Substituted aromatic amidine derivative and medicinal composition comprising the same
13. In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin
14. Rat model of arterial thrombosis of arterial thrombosis induced by ferric chloride
15. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat
16. Low-molecular weight heparins for the treatment of deep-vein thrombosis
17. Dalteparin sodium: A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
18. Optimal therapeutic ranges for unfractionated heparin and low molecular weight heparins
19. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis
20. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
21. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction
22. In vitro studies of a new synthetic thrombin inhibitor
23. Effect of thrombin inhibitors on platelet functions: Comparative analysis of DuP714 and hirudin
24. Feiba™ and Autoplex®, superimposed on a high high dose of melagatran, the active form of the oral direct thrombin inhibitor H376/95 reversed bleeding times and blood loss
25. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
26. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
27. Thrombin inhibition with inogatran for unstable angina pectoris: Evidence for reactivated ischaemia after cessation of short-term treatment
28. Guide to anticoagulant therapy Part 2: Oral anticoagulants
29. Prevention and treatment of venous thromboembolism
30. Ecarin clotting time: A predictive coagulation assay for the antithrombotic activity of argatroban in the rat